Vertex Pharma (VRTX) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex (VRTX) PT Lifted to $180 at Piper Jaffray as KALYDECO and ORKAMBI Both Beat
October 29, 2015 7:56 AM EDTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and boosted his price target on Vertex (NASDAQ: VRTX) to $180.00 (from $163.00) following solid Q3 results with KALYDECO and ORKAMBI both beating.
Tenthoff commented, "Over 3,000 patients began ORKAMBI in 3Q:15 resulting in sales of $130.8 million,... More
Baird Positive on First Quarter of Vertex (VRTX) Orkambi Sales
October 29, 2015 6:58 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $160 price target on Vertex (NASDAQ: VRTX) following results saying they are bullish on first quarter of Orkambi sales.
Skorney commented, "Right off the bat, Orkambi commanded ~35% of the patients eligible for treatment, according... More
